Expert unveils untapped potential in radiotherapy for non-small cell lung cancer

Although the standard of care for patients with stage III un-resectable non–small cell lung cancer has been concurrent chemo-radiotherapy at 60 Gy at 2 Gy/fraction, the addition of immunotherapy for those who have not progressed on chemo-radiotherapy can offer an increased benefit, explains Ashley A. Weiner, MD, PhD.